Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 11/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.55 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1484646 | 0.85 | MAP3K14 (0.48) | MAP3K14PIK3CDPIK3R1NPY5RNPC1 | |
| SCHEMBL1485037 | 0.85 | NPY5R (0.53) | MAP3K14PIK3CDPIK3R1NPY5RNPC1 | |
| SCHEMBL12535899 | 0.82 | PIK3CD (0.47) | MAP3K14PIK3CDPIK3R1NPY5RNPC1 | |
| SCHEMBL1484604 | 0.79 | PIK3CA (0.42) | MAP3K14PIK3CDPIK3R1NPY5RNPC1 | |
| SCHEMBL15192300 | 0.77 | MAP3K14 (0.49) | MAP3K14PIK3CDPIK3R1NPY5R | |
| SCHEMBL4116817 | 0.76 | MAP3K14 (0.48) | MAP3K14PIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL15192837 | 0.73 | MAP3K14 (0.50) | MAP3K14PIK3CDPIK3R1NPY5R | |
| SCHEMBL12317096 | 0.72 | MAP3K14 (0.53) | MAP3K14PIK3CDPIK3R1NPY5R | |
| SCHEMBL12535552 | 0.71 | PIK3CA (0.52) | MAP3K14PIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL15192299 | 0.71 | MAP3K14 (1.00) | MAP3K14PIK3CDPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309265-B2 | Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20140336154-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN-LA ROCHE INC. | 2014-11-13 | — | — | US | disclosed |
| US-8846762-B2 | Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2276767-B1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-20130123263-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN - LA ROCHE AG (CH) | 2013-05-16 | — | — | US | disclosed |
| US-8399690-B2 | 4,5-dihydro-6-oxa-3-thia-1-aza-benzo[e]azulene compounds | GENENTECH, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110130363-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-7928248-B2 | Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2276767-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009123971-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090247567-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336154-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, BMX, PIK3CD | MAP3K14 83/4885PIK3CD 3/4885PIK3R1 6/4885 |
| US-20110130363-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, BMX, PIK3CD | MAP3K14 83/4885PIK3CD 3/4885PIK3R1 6/4885 |
| US-20090247567-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, BMX, PIK3CD | MAP3K14 83/4885PIK3CD 3/4885PIK3R1 6/4885 |
| US-20130123263-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, BMX, PIK3CD | MAP3K14 77/4885PIK3CD 3/4885PIK3R1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.